Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
Brief Summary: The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).


Options:
A: Arm Label: Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Arm Label: Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Corticosteroid: Betamethasone, Drug: Corticosteroid: Dexamethasone, Drug: Corticosteroid: Fludrocortisone, Drug: Corticosteroid: Hydrocortisone, Drug: Corticosteroid: Meprednisone, Drug: Corticosteroid: Methylprednisolone, Drug: Corticosteroid: Prednisolone, Drug: Corticosteroid: Prednisone, Drug: Corticosteroid: Triamcinolone | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients, Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients | Intervention Type: DRUG; Name: Corticosteroid: Betamethasone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Dexamethasone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Fludrocortisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Hydrocortisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Meprednisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Methylprednisolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Prednisolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Prednisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Triamcinolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients
B: Arm Label: Daromun plus Surgery and Adjuvant therapy (Arm 1); Type: EXPERIMENTAL; Interventions: Drug: Daromun, Procedure: Surgery, Drug: Adjuvant therapy | Arm Label: Surgery and adjuvant therapy (Arm 2); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: Adjuvant therapy | Intervention Type: DRUG; Name: Daromun; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1) | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1), Surgery and adjuvant therapy (Arm 2) | Intervention Type: DRUG; Name: Adjuvant therapy; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1), Surgery and adjuvant therapy (Arm 2)
C: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
D: Arm Label: IMC-1121B (ramucirumab); Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab) | Arm Label: IMC-1121B (ramucirumab) + dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Dacarbazine | Intervention Type: BIOLOGICAL; Name: IMC-1121B (ramucirumab); Assigned to Arm(s): IMC-1121B (ramucirumab), IMC-1121B (ramucirumab) + dacarbazine | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): IMC-1121B (ramucirumab) + dacarbazine

Answer: B